- Details
- Hits: 29
Addiction has long been treated as a matter of willpower, a personal failing, or a moral weakness. But a growing body of neuroscience tells a very different story. A landmark study published in Translational Psychiatry in 2025 found that people dependent on wildly different substances share a remarkably consistent set of addiction brain patterns. This applies across alcohol, cocaine, heroin, and nicotine alike. The findings are not just academically interesting. They go to the heart of why some people struggle so profoundly to stop, and why understanding the brain is central to understanding addiction itself.
The Science Behind the Addiction Brain Patterns Discovery
Researchers at the First Hospital of Shanxi Medical University in China conducted a comprehensive meta-analysis. They pooled data from 53 resting-state functional MRI (rs-fMRI) studies. In total, the team examined 1,700 people with substance use disorder and 1,792 healthy individuals used as a comparison group.
The team focused on five key brain regions that form the core of the brain’s reward circuit: the anterior cingulate cortex, the prefrontal cortex, the striatum, the thalamus, and the amygdala. What they found was striking. Despite different substances and different stages of addiction, the same disrupted addiction brain patterns kept appearing, again and again. Nine substances were covered in total, including alcohol, nicotine, cocaine, cannabis, heroin, ketamine, amphetamine, and methamphetamine.
A Reward Circuit Gone Wrong
People with substance use disorder show significant dysfunction in the cortical-striatal-thalamic-cortical (CSTC) circuit. This is a critical neural loop. It connects the brain’s frontal regions, which govern logic and decision-making, with the striatum, the area central to motivation and reward, and with the thalamus, which relays sensory and motor signals throughout the brain.
Within this circuit, some connections become overactive. Others become underactive. The prefrontal cortex develops stronger-than-usual connections with areas involved in executive attention. But it also shows notably weaker connections with the inferior frontal gyrus, a region crucial for suppressing impulses. Put simply, the part of the brain that says “stop” loses its grip.
The striatum overconnects with the superior frontal gyrus. This suggests an exaggerated response to drug-related cues. At the same time, it underconnects with the median cingulate gyrus, a region involved in emotional regulation. The thalamus shows reduced connections across several frontal and cingulate regions. This aligns with the difficulties in concentration and impulse control that so many people with addiction report.
These substance use disorder brain changes cut across all substances studied. It did not matter whether participants relied on alcohol, heroin, or nicotine. The pattern held.
Impulsivity Is Not Just a Character Trait
One of the most compelling findings concerns impulsivity. The study found a direct statistical link between a weakened brain connection and higher scores on a validated impulsivity scale, the Barratt Impulsiveness Scale (BIS-11). The weaker the connection between the striatum and the median cingulate gyrus, the more impulsive the individual tended to be. The correlation was strong (r = 0.96, p = 0.0006), and it held even after statistical correction.
This matters enormously. People often cite impulsivity as a reason someone “chooses” to keep using substances. But this research tells a different story. For many, impulsivity reflects a measurable, observable disruption in specific brain circuits. The addiction brain patterns identified here point to a neurobiological reality, not a character flaw.
Substance Use Disorder Brain Changes Extend to Memory and Emotion
Beyond the CSTC loop, researchers identified a second disrupted circuit. This one connects the striatum to regions that handle memory and emotion, including the hippocampus and amygdala. The researchers called it the cortical-striatal-hippocampal-amygdala-cortical (CSHAC) circuit. It integrates emotional memory and sends signals back to the frontal cortex.
Disruption here helps explain something many people observe but struggle to articulate. Certain places, people, or feelings can trigger intense craving. Memory and emotion do not sit separately from addiction. The brain weaves them directly into it.
What This Means for Prevention
These substance use disorder brain changes are real, measurable, and consistent. That fact carries several important implications.
Consider what it means for early action. The longer substance use continues, the more entrenched these disruptions in the reward circuit tend to become. Intervening early, before patterns of use escalate into dependency, offers the best chance of preventing these brain changes from solidifying. Research consistently shows that prevention efforts targeting young people, before the brain’s reward and impulse control systems fully develop, deliver the greatest long-term benefit. Adolescence and early adulthood represent a window of both heightened vulnerability and genuine opportunity.
It also reframes the conversation around struggling. If someone finds it hard to stop using substances, that difficulty may partly reflect disrupted neural architecture, not simply a lack of effort. The environment matters too. Social norms, peer influence, and the easy availability of substances all shape whether someone ever reaches the point where these brain changes take hold.
Limitations Worth Noting
No single study tells the whole story, and this one is no exception. The research relied on existing data, which meant notable differences in age and gender between the addiction and healthy control groups. Women made up only 19% of the SUD group, compared to 30% of the control group. People with serious co-occurring psychiatric conditions did not appear in the original studies, which limits how broadly these findings apply in clinical settings where dual diagnosis is common.
Longitudinal studies will help determine whether these brain patterns cause addiction, result from it, or both. For now, that question stays open.
A Clearer Picture of Addiction
This research offers a clearer, more grounded picture of addiction. It is not simply a lifestyle choice. These addiction brain patterns involve measurable changes in circuits that govern reward, decision-making, impulse control, and emotional regulation. Those changes appear across substances and across people, pointing to shared mechanisms rather than isolated personal failures.
Understanding addiction as a brain-based condition does not remove personal responsibility. But it does invite a more honest, better-informed approach to the conversation. And that matters, because the way we talk about addiction shapes the decisions people make, the help they seek, and the support communities choose to offer.
(Source: WRD News)
- Details
- Hits: 19
Supervised consumption sites were sold as a disciplined, tightly monitored answer to the overdose crisis. In Alberta, the evidence suggests something far messier: weak oversight, fuzzy statistics, rising disorder, and a public policy that keeps asking citizens to trust what it does not fully measure. The claim that these facilities are “safe” has become a rhetorical shield, not a serious description of reality.
The sites may prevent some immediate drug poisonings, but the Alberta review and related reporting (among other evidence and an ever-increasing deluge of site situated negative community anecdata) raise serious concerns about transparency, neighbourhood disorder, weak treatment linkage, and a widening gap between what the sites promise and what they actually deliver.
One prominent piece of research, the Alberta review, is hard to read as anything other than a warning. It describes inconsistent record-keeping, undefined terms like “overdose” and “reversal,” and reporting practices that blurred the line between a genuine naloxone rescue and something far less dramatic, such as oxygen administration. That is not transparency. It is branding.
Then there is the small but crucial footnote in the B.C. coroner’s report: “no deaths” at supervised consumption sites does not include cases where the injury happened at the site and death occurred later in hospital. That distinction matters. It means the headline statistic can flatter the model while quietly excluding the worst outcomes. In public policy, what gets left out of the count often matters as much as what gets included.
The neighbourhood impact is where the smiley-face narrative really falls apart. Alberta’s review records persistent complaints about discarded needles, loitering, open drug use, urination, defecation, harassment, theft, and visible drug dealing around several sites. It also found that calls for service and social disorder often rose more sharply near the sites than in surrounding areas. To residents and businesses, that is not abstract “discomfort.” It is a daily loss of safety, dignity, and faith that public space still belongs to the public.
If that still sounds like a sterile list of grievances, consider the kind of firsthand account that rarely makes it into the policy briefs. Toronto-based investigative journalist Derek Finkle has described living across the street from the South Riverdale Community Health Centre in Leslieville, where an injection site began operating in late 2017. He has recounted watching the neighbourhood shift from the pre-site baseline, through the early months, into what he says became a prolonged period of escalating frustration among residents and local business owners—followed, in his telling, by a sense of being routinely dismissed when concerns were raised.
He has also described neighbours feeling compelled to document what they were seeing themselves—using a shared incident log and photographs—because official channels did not appear to capture the everyday reality on the perimeter. In a short window of roughly three and a half weeks, he says the community recorded close to 150 separate incidents. The pattern he describes mirrors the Alberta complaints almost point for point: open drug use, assaults, lewd behaviour, discarded needles, visible dealing, and the predictable intimidation that follows when drug markets harden around a fixed location.
And the policy drift is obvious. These sites were justified as a response to the opioid crisis, yet the Alberta review shows substantial methamphetamine use at some locations, including inhalation booths that widened the model beyond its original purpose. Naloxone can reverse opioids. It does nothing for stimulant psychosis, aggression, or the erratic behaviour that communities are left to absorb after users walk back onto the street. A program built for one crisis should not be judged successful simply because it keeps expanding into other crises.
The deeper failure is that supervised consumption has too often become an endpoint rather than an entry point. The Alberta review found weak evidence that sites consistently moved people into detox, treatment, or recovery, and it criticized the whole system for leaning toward “permanent maintenance” rather than genuine exit routes from addiction. That is the uncomfortable truth proponents rarely emphasize: if a site does not meaningfully connect people to recovery, then it risks becoming a holding pattern for despair.
None of this means every supervised consumption site is identical, or that every study points the same way. Some research has found reductions in poisoning mortality and ambulance calls in certain settings. But a serious society does not settle for slogans on either side. It asks harder questions: Who is being helped? Who is bearing the cost? What is actually being counted? And what happens to the neighbourhood when a policy built on compassion stops being accountable?
Finkle’s account becomes still harder to wave away because, in his telling, the frustration did not remain merely rhetorical. He has linked the breakdown in order around the site to a neighbourhood tragedy: a woman killed by stray gunfire during an alleged dispute among drug dealers nearby—an event that, he notes, only forced attention onto issues residents felt had been minimized for months. He has also pointed to the ensuing controversy in which a harm reduction worker connected to the site was arrested and charged as an accessory after the fact and with obstructing justice—an extreme and rare allegation, but a useful illustration of the broader point here: when systems are insulated from scrutiny, the public is asked to accept reassurances even when events demand documentation, clear lines of responsibility, and verifiable oversight.
The real scandal is not that the debate exists. It is that governments have allowed it to be conducted with so little rigor. If these sites are to continue, they must be subjected to clear audits, independent oversight, standardized reporting and honest reporting on treatment outcomes, neighbourhood impacts, and adverse events.
Anything less is not harm reduction – it is policy by fog.
(Source: WRD News Team)
- Details
- Hits: 45
A New Lens: Research Domain Criteria
Researchers from UCLA took a different approach. Rather than relying solely on clinical diagnoses in the NVDRS, they used the Research Domain Criteria (RDoC) framework. Developed by the National Institute of Mental Health, RDoC looks at psychological functioning across six broad domains:
- Negative valence (distress, hopelessness, anxiety)
- Positive valence (motivation, reward, substance use patterns)
- Social processes (relationships, belonging)
- Arousal processes (agitation, sleep disturbance)
- Cognitive systems (attention, memory, decision-making)
- Sensorimotor systems
Rather than asking “does this person have a diagnosis?”, RDoC asks: “in what ways was this person’s psychological functioning disrupted?”
To extract this from NVDRS death narratives, the researchers applied two machine learning methods. One was a token-based scoring system. The other was a large language model (LLM), the technology behind modern AI tools. Both had previously been validated against psychiatric inpatient records.
What the Research Found About Psychological Dysfunction and Suicide
The study analysed death records for 72,585 people who died by suicide in 2020 and 2021. These came from all 50 US states. The results were striking.
Using the LLM scoring method, more than 90% of suicide decedents showed at least one clinically significant RDoC domain score. This means evidence of dysfunction serious enough to require treatment. It was true in both law enforcement and coroner narratives.
Compare that to what the NVDRS had recorded: only 44.4% with any mental health disorder and only 27.9% described as currently depressed.
The domains most frequently elevated were negative valence and arousal processes. These capture hopelessness, distress, anxiety, and agitation. These are emotional states that do not always lead to a formal diagnosis. Yet they are deeply relevant to suicide risk and mental health outcomes.
Female decedents and younger decedents showed consistently higher levels of dysfunction across most domains. Among younger adults aged 25 to 44, clinically relevant arousal process dysfunction appeared in around 65% of law enforcement narratives. Among those aged 65 and over, this figure dropped to around 41%. Even so, dysfunction remained widespread in that older group.
Substance Use and Psychological Dysfunction and Suicide
One finding deserves particular attention. The RDoC framework links positive valence dysfunction directly to substance use patterns and their effects on reward processing. This dysfunction was significantly more common among decedents than standard NVDRS alcohol and drug measures suggested.
The standard NVDRS measure recorded problematic alcohol or drug use in 27.5% of decedents. But RDoC positive valence dysfunction, which captures disrupted reward and motivation, showed clinically relevant levels in around 31 to 41% of decedents.
Substance use does not just create health risks in isolation. It fundamentally alters how people experience reward, motivation, and relief from distress. It reshapes emotional life in ways that heighten vulnerability. That connection is essential to understand.
Why This Changes the Conversation
The traditional approach to suicide prevention has often focused on identifying people with a clinical diagnosis. If someone has a recorded diagnosis of depression or an anxiety disorder, systems are more likely to flag them for intervention. But a large proportion of people who die by suicide do not have that flag.
The RDoC approach offers a different way in. By looking at how someone is actually functioning, it is possible to detect risk that a diagnosis alone would miss.
This is especially relevant for men. Men made up 80.6% of decedents in this study. They were consistently less likely than women to have formal mental health diagnoses recorded. The suffering was still there. It was simply less likely to have been named.
(Complete Research: JAMA Network)
- Details
- Hits: 143
A groundbreaking study published in the May 2026 issue of Anesthesiology has raised serious concerns about naloxone overdose reversal when potent synthetic opioids are involved. Researchers found that one standard dose may not be enough to fully protect a person in crisis. The findings carry urgent implications for anyone on the front lines of the ongoing drug crisis.
Dr Maarten A. van Lemmen of Leiden University Medical Center in the Netherlands led the research. His team tested a single 4mg intranasal dose of Narcan against respiratory depression triggered by fentanyl and sufentanil. Both are synthetic opioids with an exceptionally strong grip on the brain’s opioid receptors.
What the Study Found About Naloxone Overdose Reversal
The trial involved 30 participants split into two groups. Twelve had never used opioids and 18 reported using opioids every day. Researchers gave each person a continuous infusion of either fentanyl or sufentanil, enough to reduce breathing by 30 to 40 per cent, before administering intranasal naloxone.
The results painted a troubling picture. Narcan restored normal breathing rates within two to four minutes across all participants. However, carbon dioxide levels recovered far more slowly, taking between 11 and 17 minutes on average. That gap matters because carbon dioxide clearance reflects whether the lungs are actually working properly.
The picture grew more concerning with sufentanil, a drug roughly ten times more potent than fentanyl. Carbon dioxide levels never fully returned to normal in a significant proportion of subjects. Only 8 of 12 opioid-naive individuals showed complete recovery. Among daily opioid users, 10 of 12 recovered fully.
“Delayed and sometimes incomplete recovery of end-tidal carbon dioxide, particularly during exposure to the high-affinity opioid sufentanil, indicates reversal inefficacy and persistence of respiratory instability,” the authors concluded.
The Gap Between Looking Awake and Being Safe
One of the most striking findings concerns how a person looks after receiving naloxone versus how their body is actually functioning. A person can appear alert and responsive long before their breathing stabilises. An accompanying editorial by James P. Rathmell, editor-in-chief of Anesthesiology and Professor of Anaesthesia at Harvard Medical School, flagged this as a serious safety risk.
“This distinction has immediate implications for patient safety, observation practices, and dosing strategies,” Dr Rathmell and co-author Steven E. Kern wrote. They explained that re-sedation and delayed respiratory instability can still occur even after intranasal naloxone administration.
Someone who appears to have woken up may still be in serious danger. This is especially true with very high-affinity synthetic opioids like sufentanil and, by extension, carfentanil, which binds to receptors even more tightly.
The Scale of the Crisis and Why Naloxone Overdose Reversal Is Harder Now
Synthetic opioids now dominate the overdose landscape. Fentanyl and related drugs account for an estimated 60 to 79 per cent of overdose deaths in the United States. Over the past two decades, roughly 800,000 Americans have died from drug overdoses, the vast majority involving potent opioids. Their molecular grip on opioid receptors makes the standard naloxone overdose reversal protocol increasingly inadequate.
The study also recorded a phenomenon known as renarcotisation. After the initial reversal, breathing rate, carbon dioxide levels, and pupil size all drifted back towards opioid-suppressed levels as naloxone wore off. A single dose simply does not last long enough when a potent opioid remains in the system.
Naloxone Overdose Reversal and Withdrawal: Another Layer of Risk
Among the 18 daily opioid users in the trial, nine experienced withdrawal symptoms after receiving naloxone. Symptoms ranged from agitation and nausea to hypertension and vomiting. Seven participants withdrew from the study because of this. For people who use opioids regularly, the reversal process can itself become a crisis.
Symptoms typically started around 20 minutes after naloxone administration and peaked at roughly 30 minutes. All resolved within two hours. Still, this reaction creates real challenges for emergency responders working in unpredictable settings.
What This Means for Overdose Response
The study’s authors are direct on what practitioners should take away. A single naloxone dose cannot reliably reverse overdoses involving high-affinity synthetic opioids. Calling emergency services immediately remains essential, even when the drug appears to have worked. Multiple doses may be necessary. Close monitoring must continue long after the person regains consciousness.
Current overdose response guidelines developed around heroin, which binds to receptors far less powerfully than fentanyl. The drug supply has shifted dramatically. Those protocols now need urgent revision.
“Further studies are needed to address optimal naloxone doses and alternative formulations to address high-dose potent opioid threats,” the research team noted.
A Call for Updated Thinking on Intranasal Naloxone
The study does carry limitations. Laboratory infusions differ from real-world overdoses, where opioid levels spike then fall naturally. That natural decline may assist recovery in ways the experiment could not replicate. The level of respiratory depression induced, 30 to 40 per cent below baseline, was also moderate. Real overdoses often involve complete cessation of breathing, making a single intranasal naloxone dose even less likely to suffice.
A separate study by the same team found that when fentanyl caused full apnea, patients needed two to four Narcan doses to restore normal breathing. Together, the findings confirm that naloxone overdose reversal is not a one-and-done solution against today’s synthetic drugs.
Naloxone saves lives. But it is not a guarantee, and it was never a substitute for emergency medical care. Knowing its limits and acting on that knowledge could be the difference between survival and tragedy.
(Source: WRD News)
- Details
- Hits: 106
Young people struggling with youth drug treatment needs have long been underserved by a system built around adults. That is now changing. The American Society of Addiction Medicine (ASAM) has published a landmark framework dedicated entirely to substance use disorder care for adolescents and young adults under 25, separating their standards from adult guidance for the first time.
The new volume, titled the Adolescent and Transition-Aged Youth edition of The ASAM Criteria, sets out the full range of services that should be available to every young patient. Previously, adolescent addiction treatment standards sat buried within adult-focused criteria, a setup that many clinicians had criticised for years.
Brain development continues well into a person’s mid-twenties. That biological reality shapes the entire framework. Young people are not simply smaller adults, and the risks they face from substance use reflect that difference.
Why Youth Drug Treatment Needs Its Own Framework
The numbers make a sobering case. Around 80% of adults living with substance use disorder started using substances before the age of 18. Those who begin before 15 are 6.5 times more likely to develop a dependency than those who wait until 21 or older. Early exposure does not just raise risk. It can reshape development, delay the acquisition of life skills, and set a difficult course for decades to come.
“Ongoing brain development during these formative years puts youth at a greater risk of developing the disease of addiction, which can lead to poor health outcomes and delayed life skill development,” said Dr Corey Waller, editor-in-chief of the new volume.
The ASAM now recommends early intervention for any young person already using substances and showing signs of rapid escalation. Waiting for a formal diagnosis before acting is no longer the preferred approach.
Adolescent Addiction Treatment: A Holistic, Family-Centred Model
The updated standards place the young person firmly at the centre, but they also widen the lens considerably. The framework promotes a model that brings in mental health services, connects with schools and community networks, and treats prevention as seriously as treatment itself.
This matters because youth drug treatment challenges rarely travel alone. Most adolescents dealing with substance-related difficulties also carry co-occurring mental health conditions. The new guidance pushes clinicians to address both at the same time, not in sequence.
The continuum of care expands too. New service levels include ongoing remission monitoring and integrated withdrawal management within youth-specific programmes. These are areas that existing guidance had largely overlooked.
Rising Risks Make the Case for Change
The clinical picture for young people has grown more complex in recent years. Fentanyl and other high-potency substances now reach adolescents far more readily than before. Clinicians report encountering levels of risk in young patients that would have been uncommon a decade ago.
“While there will be challenges to overcome to make this vision a reality, we must commit to building systems and payment models capable of delivering effective interventions and treatments for all young people who need them,” said Dr Waller.
Putting the New Standards Into Practice
ASAM presented the new criteria on 25 March at the Joint Meeting on Youth Prevention, Treatment, and Recovery. The Hazelden Betty Ford Foundation published the complete volume online and will release a print edition in June.
The Foundation also built a digital interface to help clinicians across the full care team put adolescent addiction treatment into practice without friction.
“The ASAM Criteria’s new adolescent treatment standards represent a tremendous opportunity to further elevate and individualise care for our nation’s children and young adults,” said Dr Joseph Lee, president and chief executive of the Hazelden Betty Ford Foundation.
The framework asks more than clinicians to act. It calls on commissioners, policymakers and system leaders to fund and build the infrastructure these standards require. With the evidence pointing clearly to adolescence as the window where intervention matters most, getting that infrastructure right carries consequences that stretch well beyond the clinic.
(Source: WRD News)
- What You Drink and Smoke at 20 Could Rob You of Your Memory at 65
- The Hidden Crisis: Violence Against Women Who Use Drugs and Why So Few Get Help
- The Powerful Link Between Spirituality and Reduced Alcohol and Drug Use
- Prayer, Meditation and Faith Could Cut Your Risk of Alcohol and Drug Misuse, Harvard Study Finds